Aurisco(SH:605116) Zheng Quan Zhi Xing·2025-08-29 16:18Group 1 - The third meeting of the board of directors of Aorite Pharmaceutical Co., Ltd. was held on August 27, 2025, with all 9 directors present, and the resolutions made were deemed legal and effective [1] - The board approved the use of up to RMB 100 million of temporarily idle raised funds for cash management, investing in safe and liquid financial products with a maturity of no more than 12 months [2][3] - The company plans to hold its first extraordinary general meeting of 2025 on September 26, 2025, to discuss various proposals, including changes to governance structures [7] Group 2 - The board's resolutions included the approval of a special report on the actual use of raised funds, which will be disclosed on August 29, 2025 [2] - The company is set to revise its governance documents in accordance with the latest regulatory requirements from the China Securities Regulatory Commission and the Shanghai Stock Exchange [6] - The board's decisions regarding the cancellation of the supervisory board and changes to the company's registered capital will also be submitted for shareholder approval [4][5]